Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease

NCT00955422 | Completed

• 2 other identifiers: 09019809-M-0198
• Study Type: observational
• Target: 197
• Locations: 1 country
• Sites: 1

Brief Summary

Background:

• Individuals who demonstrate symptoms of Alzheimer s disease, such as progressive memory loss, may be eligible to participate in National Institutes of Health research studies. However, other physical and psychological conditions may produce symptoms similar to those of Alzheimer s disease. To determine whether a patient meets the eligibility criteria to participate in a research protocol, researchers must perform a series of diagnostic tests and procedures.
• These evaluations are designed to evaluate a participant s general medical condition (for example, blood tests and neurological exams) and to confirm a diagnosis or rule out an individual for consideration. They maximize the safety for participants in studies conducted at the National Institutes of Mental Health. Objective: \- To determine the eligibility of individuals for active Alzheimer s disease protocols. Eligibility: \- Individuals 45 years of age and older who have been having memory problems that have been getting worse with time and have been interfering with everyday life. Design:
• Required tests and procedures for various research studies may include the following:
• Medical history and physical examination, including a psychiatric evaluation.
• Neuropsychological tests to test memory, mood, concentration, and thought processes.
• Blood and urine tests.
• Imaging studies (X-rays, magnetic resonance imaging (MRI), computerized tomography (CT), positron emission tomography (PET)).
• Additional blood samples and MRI data for future use.
• After all eligibility assessments are complete, participants may be offered participation in one or more research protocols

Conditions

Alzheimer's Disease

Keywords

Diagnosis; Alzheimer's Disease; Memory Disorder; Dementia; Alzheimer Disease; Memory Loss

Eligibility Criteria

• Age: 45 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients and healthy volunteers must be age 45 or older.
• Patients must have a history of progressive memory impairment.
• Patients must have a caregiver who is willing to accompany the subject to the NIH.

You may not qualify if:

• The diagnosis of a different type of dementia, including frontotemporal dementia, normal pressure hydrocephalus, Lewy body dementia, Parkinson s disease dementia, Huntington s disease, or vascular dementia.
• Pregnant women. Women of childbearing potential will be screened by history for the possibility of pregnancy and undergo a urine pregnancy test.
• Any medical contraindication to the procedures performed in the study, or any current severe medical or psychiatric illness other than Alzheimer s disease.
• Behavioral symptoms that would preclude the gathering of data for the study, or advanced disease such that subjects cannot provide assent.
• The diagnosis of a brain disorder.
• Pregnant women.
• Any medical contraindication to the procedures performed in the study, or any current severe medical or psychiatric illness.

Sponsors & Collaborators

• National Institute of Mental Health (NIMH): lead

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (5)

• Gorshow S. Alzheimer's disease and managed care: a convincing case for action. Manag Care Interface. 2007 Mar;20(3):26-7.

  PMID: 17458478 BACKGROUND

• Wimo A, Jonsson L, Winblad B. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord. 2006;21(3):175-81. doi: 10.1159/000090733. Epub 2006 Jan 9.

  PMID: 16401889 BACKGROUND

• Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007 Aug;6(8):734-46. doi: 10.1016/S1474-4422(07)70178-3.

  PMID: 17616482 BACKGROUND

• Kreisl WC, Lyoo CH, Liow JS, Snow J, Page E, Jenko KJ, Morse CL, Zoghbi SS, Pike VW, Turner RS, Innis RB. Distinct patterns of increased translocator protein in posterior cortical atrophy and amnestic Alzheimer's disease. Neurobiol Aging. 2017 Mar;51:132-140. doi: 10.1016/j.neurobiolaging.2016.12.006. Epub 2016 Dec 16.

  PMID: 28068564 DERIVED

• Kreisl WC, Lyoo CH, Liow JS, Wei M, Snow J, Page E, Jenko KJ, Morse CL, Zoghbi SS, Pike VW, Turner RS, Innis RB. (11)C-PBR28 binding to translocator protein increases with progression of Alzheimer's disease. Neurobiol Aging. 2016 Aug;44:53-61. doi: 10.1016/j.neurobiolaging.2016.04.011. Epub 2016 Apr 27.

  PMID: 27318133 DERIVED

MeSH Terms

Conditions

Alzheimer Disease; Disease; Memory Disorders; Dementia

Condition Hierarchy (Ancestors)

Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Neurobehavioral Manifestations; Neurologic Manifestations; Signs and Symptoms

Study Officials

• Robert B Innis, M.D.

  National Institute of Mental Health (NIMH)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Time Perspective: PROSPECTIVE
• Sponsor Type: NIH

Study Record Dates

• First Submitted: August 7, 2009
• First Posted: August 10, 2009
• Study Start: July 31, 2009
• Study Completion: July 6, 2017
• Last Updated: July 5, 2018

Record last verified: 2017-07-06

Locations

US (1)